Risk-Group Classification of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia - NCT00482352-Calgary - 005 (Clinical Trial 171499)
Permalink: http://www.ClinicalConnection.com/exp/ExpandedPatientViewStudy171499.aspx
|
** Please review additional "Nearby Studies" on right ----->
This is an archived study that is no longer available, if you
would like to find active studies please search our studies.
|
|
 |
 |
|
| City: |
|
Calgary |
|
Country:
|
|
Canada |
|
|
|
| Conditions: |
|
Leukemia |
| Purpose: |
|
RATIONALE: Developing a risk-group classification guide may help doctors assign patients
with newly diagnosed acute lymphoblastic leukemia to treatment clinical trials.
PURPOSE: This clinical trial is studying risk-group classification of patients with newly
diagnosed acute lymphoblastic leukemia.
|
| Study summary: |
|
OBJECTIVES:
- Provide a classification guide that will organize the clinical and laboratory data
necessary for assigning each patient with newly diagnosed acute lymphoblastic leukemia
(ALL) to a specific treatment clinical trial.
- Provide an administrative base to capture classification data for correlative studies
accompanying current Children's Oncology Group (COG) ALL treatment clinical trials.
- Provide a central reference guide for all required and research only ALL studies that
will be conducted at local and reference laboratories.
- Provide a mechanism for optional banking of leukemia and germline specimens for current
and future research.
OUTLINE: Patients undergo blood collection and bone marrow biopsies at baseline and at the
end of induction therapy for immunophenotyping for marker identification; molecular testing
for translocations; trisomy analysis by fluorescence in situ hybridization (FISH); and DNA
ploidy. Immunophenotype results obtained on this study are used to determine the patient's
assignment to specific treatment clinical trials (consistent with acute lymphoblastic
leukemia).
After completion of induction therapy, patients are followed once or twice annually. |
| Criteria: |
|
DISEASE CHARACTERISTICS:
- Newly diagnosed acute lymphoblastic leukemia, defined by any of the following:
- At least 25% blasts in the bone marrow
- Absolute blast count at least 10,000/mm^3, if bone marrow aspiration is not
performed
- No prior registration on this study
PATIENT CHARACTERISTICS:
Age
- Under 31
Performance status
- Not specified
Life expectancy
- Not specified
Hematopoietic
- Not specified
Hepatic
- Not specified
Renal
- Not specified
PRIOR CONCURRENT THERAPY:
Biologic therapy
- Not specified
Chemotherapy
- Not specified
Endocrine therapy
- Not specified
Radiotherapy
- Not specified
Surgery
- Not specified |
|
|
|
|
|
|
|
|
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
|
| Trials Alerts: |
|
If you would like to be
notified of new clinical trials as they become available please
register for a free account.
|
|
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
October 20, 2009 |
Modifications to
this listing: |
|
Only selected fields are shown, please use the link
above to view all information about this clinical trial. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Clinical trials are medical research studies designed to test the safety and/or
effectiveness of new drugs, devices, or treatments in humans. These studies are
conducted worldwide for a range of conditions and illnesses. Learn more about
clinical research and participating in a study at
About Clinical Trials.
|
|
|
|
|